Molecular and cellular biology of prostate cancer
暂无分享,去创建一个
[1] D. Peehl. Oncogenes in prostate cancer. An update , 1993, Cancer.
[2] J. Pancrazio,et al. Voltage-activated K+ conductance and cell proliferation in small-cell lung cancer. , 1993, Anticancer research.
[3] S. Dedhar,et al. Identification of a novel form of the alpha 3 integrin subunit: covalent association with transferrin receptor. , 1995, The Biochemical journal.
[4] C. Turc‐Carel,et al. Chromosomes in solid tumors and beyond. , 1988, Cancer research.
[5] P. Reinach,et al. Effects of androgen on intracellular calcium of LNCaP cells. , 1991, Biochemical and biophysical research communications.
[6] K. Pienta,et al. Effect of pentosan, a novel cancer chemotherapeutic agent, on prostate cancer cell growth and motility , 1992, The Prostate.
[7] D. Neal,et al. Peptide growth factors in the prostate as mediators of stromal epithelial interaction. , 1996, British journal of urology.
[8] A. Schuurmans,et al. Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell LNCaP , 1988, The Prostate.
[9] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[10] J. Barnard,et al. Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor. , 1995, Cancer research.
[11] Lars Holmgren,et al. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.
[12] P. Abel,et al. Expression and functional analysis of voltage-activated Na+ channels in human prostate cancer cell lines and their contribution to invasion in vitro. , 1997, The American journal of pathology.
[13] D. Isenberg,et al. Serum metalloproteinases and their inhibitors: markers for malignant potential. , 1994, British Journal of Cancer.
[14] R. Miesfeld,et al. Functional characterizations of the androgen receptor confirm that the molecular basis of androgen action is transcriptional regulation. , 1990, Molecular endocrinology.
[15] C. Chang,et al. Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. , 1992, The Journal of urology.
[16] W. Lee,et al. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[17] R. Franklin,et al. Effect of prolactin on the prostate , 1994, The Prostate.
[18] L. Chung,et al. Hormone-induced morphogenesis and growth: role of mesenchymal-epithelial interactions. , 1983, Recent progress in hormone research.
[19] S. Magnuson,et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. , 1996, Cancer research.
[20] S. Dedhar,et al. Specific alterations in the expression of α3β1 and α6β4 integrins in highly invasive and metastatic variants of human prostate carcinoma cells selected by in vitro invasion through reconstituted basement membrane , 1993, Clinical & Experimental Metastasis.
[21] R. Cohen,et al. The neuroendocrine cell population of the human prostate gland. , 1993, The Journal of urology.
[22] E. Hedley‐Whyte,et al. Prognostic role of urokinase-type plasminogen activator in human gliomas. , 1995, The American journal of pathology.
[23] A. Belldegrun,et al. In vitro modulation of tumor progression‐associated properties of hormone refractory prostate carcinoma cell lines by cytokines , 1996, Cancer.
[24] D. Paulson,et al. Spontaneous metastasis of cells of the human prostate carcinoma cell line PC-3 in athymic nude mice. , 1982, The Journal of urology.
[25] H. Klocker,et al. Androgen signal transduction and prostatic carcinoma , 2004, World Journal of Urology.
[26] M. Susin,et al. Mutational status of codons 12 and 13 of the N- and K-ras genes in tissue and cell lines derived from primary and metastatic prostate carcinomas. , 1993, Cancer investigation.
[27] D. Hanahan,et al. Switch to the angiogenic phenotype during tumorigenesis. , 1991, Princess Takamatsu symposia.
[28] J. Lechner,et al. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). , 1979, Investigative urology.
[29] J. Folkman. Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.
[30] E. Wanke,et al. Response to fibronectin–integrin interaction in leukaemia cells: delayed enhancing of a K+ current , 1992, Proceedings of the Royal Society of London. Series B: Biological Sciences.
[31] C. Higgins. Volume‐activated chloride currents associated with the multidrug resistance P‐glycoprotein. , 1995, The Journal of physiology.
[32] Chawnshang Chang,et al. Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates , 1990, The Prostate.
[33] W. Wonderlin,et al. Changes in membrane potential during the progression of MCF‐7 human mammary tumor cells through the cell cycle , 1995, Journal of cellular physiology.
[34] C. Polychronakos,et al. Proteinolytic activity against IGF-binding proteins involved in the paracrine interactions between prostate adenocarcinoma cells and osteoblasts. , 1992, Anticancer research.
[35] R. Sadasivan,et al. Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer. , 1993, The Journal of urology.
[36] J. Schalken,et al. Down modulation of fibronectin messenger RNA in metastasizing rat prostatic cancer cells revealed by differential hybridization analysis. , 1988, Cancer research.
[37] W. Wonderlin,et al. Inhibition of ATP‐sensitive potassium channels causes reversible cell‐cycle arrest of human breast cancer cells in tissue culture , 1995, Journal of cellular physiology.
[38] B. Allolio,et al. Antiproliferative and angiostatic activity of suramin analogues. , 1995, Cancer research.
[39] B. Tribukait. Flow cytometry in assessing the clinical aggressiveness of genito-urinary neoplasms , 1987, World Journal of Urology.
[40] W. Haenszel,et al. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. , 1968, Journal of the National Cancer Institute.
[41] D. Pa. Neuroendocrine differentiation in the precursors of prostate cancer , 1996 .
[42] U. Bergerheim,et al. Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma , 1991, Genes, chromosomes & cancer.
[43] T. Nakajima,et al. Nitric oxide-mediated apoptosis in murine mastocytoma. , 1994, Biochemical and biophysical research communications.
[44] K. Cooney,et al. Distinct regions of allelic loss on 13q in prostate cancer. , 1996, Cancer research.
[45] J. Southgate,et al. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ , 1989, Cell.
[46] D. Rose,et al. Production of epidermal growth factor and transforming growth factor‐α by the androgen‐responsive LNCaP human prostate cancer cell line , 1990, The Prostate.
[47] S. J. Higgins,et al. The endocrinology and developmental biology of the prostate. , 1987, Endocrine reviews.
[48] R. Kiss,et al. Influence of dihydrotestosterone, epidermal growth factor, and basic fibroblast growth factor on the cell kinetics of the PC3, DUI45, and LNCap prostatic cancer cell lines: Relationship with DNA ploidy level , 1995, The Prostate.
[49] L M Loew,et al. Electric field-directed fibroblast locomotion involves cell surface molecular reorganization and is calcium independent , 1994, The Journal of cell biology.
[50] W Blumenfeld,et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.
[51] J. McNeal,et al. Origin and development of carcinoma in the prostate , 1969, Cancer.
[52] G. Murphy,et al. LNCaP model of human prostatic carcinoma. , 1983, Cancer research.
[53] E. Gelmann,et al. p53 oncogene mutations in human prostate cancer specimens. , 1994, The Journal of urology.
[54] E. Liu,et al. p53 gene alterations in human prostate carcinoma. , 1993, The Journal of urology.
[55] H. Tucker,et al. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. , 1996, Urology.
[56] W. W. Nichols,et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. , 1993, Journal of the National Cancer Institute.
[57] D. Bostwick. Progression of prostatic intraepithelial neoplasia to early invasive adenocarcinoma. , 1996, European urology.
[58] S. Piantadosi,et al. Clinical evidence for and implications of the multistep development of prostate cancer. , 1990, The Journal of urology.
[59] Austin Ge,et al. Antibodies to ras oncogene p21 proteins lack immunohistochemical specificity for neoplastic epithelium in human prostate tissue. , 1989 .
[60] W. Isaacs,et al. Androgen receptor gene mutations in human prostate cancer. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[61] J. Barrett,et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. , 1995, Science.
[62] M. Kattan,et al. Perineural invasion of prostate carcinoma cells is associated with reduced apoptotic index , 1996, Cancer.
[63] J. A. van der Korput,et al. Expression of cellular oncogenes in human prostatic carcinoma cell lines. , 1985, Biochemical and biophysical research communications.
[64] J. Heino. Biology of tumor cell invasion: Interplay of cell adhesion and matrix degradation , 1996, International journal of cancer.
[65] Thomas J. White,et al. PCR protocols: a guide to methods and applications. , 1990 .
[66] V. Jackson. Studies on histone organization in the nucleosome using formaldehyde as a reversible cross-linking agent , 1978, Cell.
[67] K. Yamamoto,et al. Signal transduction by steroid hormones: nuclear localization is differentially regulated in estrogen and glucocorticoid receptors. , 1990, Cell regulation.
[68] W. Sakr,et al. Fluorescence in situ hybridization analysis of 8p allelic loss and chromosome 8 instability in human prostate cancer. , 1994, Cancer research.
[69] J. Sklar,et al. DNA hybridization in diagnostic pathology. , 1985, Human pathology.
[70] M. R. Cooper,et al. Antitumor activity of suramin in hormone‐refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables , 1995, Cancer.
[71] Andrew A. Marino,et al. Association between cell membrane potential and breast cancer. , 1994, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
[72] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[73] W. Lee,et al. A case of synovial sarcoma with abnormal expression of the human retinoblastoma susceptibility gene. , 1988, Human pathology.
[74] P. Ekman,et al. Steroid receptor profile in human prostate cancer metastases as compared with primary prostatic carcinoma , 1991, The Prostate.
[75] T. Stamey,et al. Activated ki‐ras oncogene in human prostatic adenocarcinoma , 1987, The Prostate.
[76] Jorma Isola,et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.
[77] W. Birchmeier,et al. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. , 1994, Biochimica et biophysica acta.
[78] W. Isaacs,et al. ras gene mutations in human prostate cancer. , 1990, Cancer research.
[79] J. Moul,et al. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. , 1994, Cancer research.
[80] J. Epstein,et al. Nucleoli in low-grade prostate adenocarcinoma and adenosis. , 1993, Human pathology.
[81] C. Marshall. Tumor suppressor genes , 1991, Cell.
[82] A. Schally,et al. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. , 1994, Cancer research.
[83] Chung Lee,et al. In vivo andin vitro approaches to study metastasis in human prostatic cancer , 1993, Cancer and Metastasis Reviews.
[84] M. Brawer,et al. Topography of neovascularity in human prostate carcinoma , 1995, Cancer.
[85] P. Scardino,et al. Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study. , 1993, Human pathology.
[86] M. Barbacid,et al. ras oncogenes: their role in neoplasia , 1990, European journal of clinical investigation.
[87] M. Kanzaki,et al. Expression of Calcium-permeable Cation Channel CD20 Accelerates Progression through the G1 Phase in Balb/c 3T3 Cells(*) , 1995, The Journal of Biological Chemistry.
[88] C. Collins,et al. Prognostic value of c-erbB-2 and epidermal growth factor receptor in stage A1 (T1a) prostatic adenocarcinoma. , 1994, British journal of urology.
[89] U. Stein,et al. Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. , 1994, Human pathology.
[90] L. Liotta,et al. Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. , 1995, Cancer research.
[91] W. Sakr,et al. Cytogenetics of primary prostatic adenocarcinoma. Clonality and chromosome instability. , 1992, Cancer genetics and cytogenetics.
[92] William B. Isaacs,et al. Establishment and characterization of seven dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers , 1986 .
[93] P. Wingo,et al. Cancer statistics, 1996 , 1996, CA: a cancer journal for clinicians.
[94] E. Wanke,et al. Integrin-mediated neurite outgrowth in neuroblastoma cells depends on the activation of potassium channels , 1993, The Journal of cell biology.
[95] M. Steiner,et al. Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro. , 1992, Molecular endocrinology.
[96] M. Neumaier,et al. CD66a (BGP), an adhesion molecule of the carcinoembryonic antigen family, is expressed in epithelium, endothelium, and myeloid cells in a wide range of normal human tissues. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[97] H. Klocker,et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. , 1995, European urology.
[98] M. Greenberg,et al. L-type voltage-sensitive calcium channel activation stimulates gene expression by a serum response factor-dependent pathway. , 1994, The Journal of biological chemistry.
[99] C. Eaton,et al. Growth factor involvement and oncogene expression in prostatic tumours. , 1988, Journal of steroid biochemistry.
[100] R. White,et al. Suppression of the malignant phenotype of human prostate cancer cell line PPC-1 by introduction of normal fragments of human chromosome 10. , 1996, Cancer research.
[101] H. Poulsen,et al. Transforming growth factor and cancer , 1995 .
[102] R C Smith,et al. Effect of epidermal growth factor on prostate cancer cell line PC3 growth and invasion , 1994, The Prostate.
[103] D. D'Amico,et al. Sex steroids up-regulate E-cadherin expression in hormone-responsive LNCaP human prostate cancer cells. , 1995, Biochemical and biophysical research communications.
[104] F. Collins,et al. Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.
[105] T. Stephenson,et al. Absence of S‐100 protein in prostatic glands , 1988, Histopathology.
[106] S. Dedhar,et al. Stimulation of tyrosine phosphorylation of distinct proteins in response to antibody-mediated ligation and clustering of alpha 3 and alpha 6 integrins. , 1995, Journal of cell science.
[107] S. Batra,et al. Effect of calcium and calcium antagonists on 45Ca influx and cellular growth of human prostatic tumor cells , 1991, The Prostate.
[108] J. Moul,et al. Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. , 1993, The Journal of urology.
[109] T. Vogt,et al. Comparison of DNA ploidy in prostatic intraepithelial neoplasia and invasive carcinoma of the prostate: an image cytometric study. , 1994, Human pathology.
[110] E. Greenberg,et al. Changes in prostate cancer incidence and treatment in USA , 1994, The Lancet.
[111] D. Rose,et al. Autocrine regulation of DU145 human prostate cancer cell growth by epidermal growth factor‐related polypeptides , 1991, The Prostate.
[112] V. Reuter,et al. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma , 1993, Cancer.
[113] D. Grignon,et al. Interobserver Reproducibility in the Diagnosis of Prostatic Intraepithelial Neoplasia , 1995, The American journal of surgical pathology.
[114] T. Tong,et al. Cancer statistics, 1994 , 1994, CA: a cancer journal for clinicians.
[115] Ankita Patel,et al. Frequency and pattern of karyotypic abnormalities in human prostate cancer. , 1990, Cancer research.
[116] D. Hixson,et al. Structure and function of C-CAM1: effects of the cytoplasmic domain on cell aggregation. , 1995, The Biochemical journal.
[117] H. Perlman,et al. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. , 1995, Cancer research.
[118] P. diSant’Agnese,et al. The neuroendocrine prostate: characterization and quantitation of calcitonin in the human gland. , 1989, The Journal of urology.
[119] W. Cavenee,et al. Molecular mechanisms of oncogenesis. , 1989, Laboratory investigation; a journal of technical methods and pathology.
[120] J. Wrathall,et al. Regulation of growth by a nerve growth factor-like protein which modulates paracrine interactions between a neoplastic epithelial cell line and stromal cells of the human prostate. , 1991, Cancer research.
[121] W. Isaacs,et al. Allelic loss of chromosomes 16q and 10q in human prostate cancer. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[122] A. Schwab,et al. Oscillating activity of a Ca(2+)-sensitive K+ channel. A prerequisite for migration of transformed Madin-Darby canine kidney focus cells. , 1994, The Journal of clinical investigation.
[123] J. Moul,et al. Detection of RAS mutations in archival testicular germ cell tumors by polymerase chain reaction and oligonucleotide hybridization , 1992, Genes, chromosomes & cancer.
[124] N. Kyprianou,et al. Association states of androgen receptors in nuclei of human benign hypertrophic prostate , 1986, The Prostate.
[125] A. Partin,et al. Early cell motility changes associated with an increase in metastatic ability in rat prostatic cancer cells transfected with the v-Harvey-ras oncogene. , 1988, Cancer research.
[126] J. Trapman,et al. Two different, overlapping pathways of transcription initiation are active on the TATA-less human androgen receptor promoter. The role of Sp1. , 1993, The Journal of biological chemistry.
[127] J. Milios,et al. Cytokeratin and vimentin intermediate filament proteins in benign and neoplastic prostatic epithelium , 1988, Histopathology.
[128] N. Kyprianou,et al. Activation of a Ca2+−Mg2+‐dependent endonuclease as an early event in castration‐induced prostatic cell death , 1988, The Prostate.
[129] H. Kumagai,et al. Transglycosylation activity of Mucor hiemalis endo-beta-N-acetyl-glucosaminidase which transfers complex oligosaccharides to the N-acetylglucosamine moieties of peptides. , 1994, Biochemical and biophysical research communications.
[130] J. Vane,et al. Rat endothelin is a vasodilator in the isolated perfused mesentery of the rat. , 1989, European journal of pharmacology.
[131] M. Stearns,et al. Autocrine factors, type IV collagenase secretion and prostatic cancer cell invasion , 1993, Cancer and Metastasis Reviews.
[132] M. Sokolovsky,et al. Evidence for involvement of the voltage-dependent Na+ channel gating in depolarization-induced activation of G-proteins. , 1993, The Journal of biological chemistry.
[133] R. Matusik,et al. Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. , 1986, Cancer research.
[134] M. Brawer,et al. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity , 1994, Cancer.
[135] E. Neher. Ion channels for communication between and within cells , 1992, Neuron.
[136] S. Woolf. Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. , 1995, The New England journal of medicine.
[137] S. H. Lin,et al. Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: a preclinical study. , 1995, Cancer research.
[138] R. Nagle,et al. Expression of hemidesmosomal and extracellular matrix proteins by normal and malignant human prostate tissue. , 1995, The American journal of pathology.
[139] A. Melman,et al. Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer , 1995, Nature Medicine.
[140] D. Djakiew,et al. Stromal-epithelial paracrine interactions in the neoplastic rat and human prostate. , 1993, Advances in experimental medicine and biology.
[141] D. Bostwick,et al. Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. , 1995, Cancer research.
[142] R. Nagle,et al. Adhesion molecules, extracellular matrix, and proteases in prostate carcinoma. , 1994, Journal of cellular biochemistry. Supplement.
[143] O. Cussenot,et al. A microdissection approach to detect molecular markers during progression of prostate cancer. , 1995, British Journal of Cancer.
[144] D. Albanes,et al. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. , 1994, The New England journal of medicine.
[145] T. Sekiya,et al. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[146] Y. Huang,et al. Potassium channel induction by the Ras/Raf signal transduction cascade. , 1994, The Journal of biological chemistry.
[147] P. Kostenuik,et al. Bone cell matrix promotes the adhesion of human prostatic carcinoma cells via the α2β1 integrin , 2004, Clinical & Experimental Metastasis.
[148] S. H. Lin,et al. Androgen regulation of cell adhesion molecule gene expression in rat prostate during organ degeneration. C-CAM belongs to a class of androgen-repressed genes associated with enriched stem/amplifying cell population after prolonged castration. , 1994, The Journal of biological chemistry.
[149] R. Weinberg,et al. Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encoded protein. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[150] J D Siegal,et al. Enhanced expression of the c‐myc protooncogene in high‐grade human prostate cancers , 1988, The Prostate.
[151] David G. Bostwick,et al. High grade prostatic intraepithelial neoplasia. The most likely precursor of prostate cancer , 1995 .
[152] R. Nagle,et al. Integrin α6 expression in human prostate carcinoma cells is associated with a migratory and invasive phenotypein vitro andin vivo , 1995, Clinical & Experimental Metastasis.
[153] J. Massagué,et al. Early gene responses to transforming growth factor-beta in cells lacking growth-suppressive RB function , 1991, Molecular and cellular biology.
[154] F. McCormick,et al. Activators and effectors of ras p21 proteins. , 1994, Current opinion in genetics & development.
[155] J. Srigley,et al. Basal epithelial cells of human prostate gland are not myoepithelial cells. A comparative immunohistochemical and ultrastructural study with the human salivary gland. , 1990, The American journal of pathology.
[156] R. Evans,et al. The steroid and thyroid hormone receptor superfamily. , 1988, Science.
[157] P. Walsh,et al. Subcellular distribution of androgen receptors in human normal, benign hyperplastic, and malignant prostatic tissues: characterization of nuclear salt-resistant receptors. , 1983, Cancer research.
[158] J. Mendelsohn,et al. Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor alpha. , 1991, Cancer research.
[159] J. Nelson,et al. Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate , 1995, Nature Medicine.
[160] G. R. Taylor,et al. PCR: a practical approach. , 1991 .
[161] J. Isaacs,et al. Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers , 1995, The Prostate.
[162] J. Schalken,et al. Decreased expression of E-cadherin in the progression of rat prostatic cancer. , 1992, Cancer research.
[163] G. Miller,et al. Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway. , 1996, Endocrinology.
[164] E. Barrack,et al. Modulation of transforming growth factor beta 1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. , 1995, Cancer research.
[165] A. Brothman,et al. Characterization of 10 marker chromosomes in a prostatic cancer cell line by in situ hybridization. , 1992, Cytogenetics and cell genetics.
[166] B. Vogelstein,et al. A genetic model for colorectal tumorigenesis , 1990, Cell.
[167] P. Walsh,et al. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. , 1993, Cancer research.
[168] J. Trapman,et al. Androgen receptor abnormalities , 1991, The Journal of Steroid Biochemistry and Molecular Biology.
[169] H. Morrison,et al. Farming and prostate cancer mortality. , 1993, American journal of epidemiology.
[170] U. Falkmer. Methodologic sources of errors in image and flow cytometric DNA assessments of the malignancy potential of prostatic carcinoma. , 1992, Human pathology.
[171] D. Bostwick,et al. Loss of chromosome arm 8p loci in prostate cancer: Mapping by quantitative allelic imbalance , 1994, Genes, chromosomes & cancer.
[172] A. Belldegrun,et al. Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[173] J. Ramsdell,et al. Maitotoxin, a calcium channel activator, inhibits cell cycle progression through the G1/S and G2/M transitions and prevents CDC2 kinase activation in GH4C1 cells , 1996, Journal of cellular physiology.
[174] P. Walsh. Using Prostate-specific Antigen To Diagnose Prostate Cancer: Sailing in Uncharted Waters , 1993, Annals of Internal Medicine.
[175] W. Lee,et al. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. , 1990, Science.
[176] F. S. French,et al. Oncogene expression in prostate cancer: Dunning R3327 rat dorsal prostatic adenocarcinoma system , 1988, The Prostate.
[177] E. Johnson,et al. Effects of nerve growth factor on rat peritoneal mast cells. Survival promotion and immediate-early gene induction. , 1994, The Journal of biological chemistry.
[178] J. Kim,et al. Inhibition of prostatic tumor cell proliferation by suramin: alterations in TGF alpha-mediated autocrine growth regulation and cell cycle distribution. , 1991, The Journal of urology.
[179] J. Ferlay,et al. Estimates of the worldwide incidence of eighteen major cancers in 1985 , 1993, International journal of cancer.
[180] T. P. Pretlow,et al. Expression of E-cadherin in primary and metastatic prostate cancer. , 1996, The American journal of pathology.
[181] J. Barrett,et al. An amino-terminal c-myc domain required for neoplastic transformation activates transcription , 1990, Molecular and cellular biology.
[182] E. Rimm,et al. A prospective study of dietary fat and risk of prostate cancer. , 1993, Journal of the National Cancer Institute.
[183] P. Green,et al. Identification of p53 gene mutations in bladder cancers and urine samples. , 1991, Science.
[184] H. Bonkhoff,et al. Widespread distribution of nuclear androgen receptors in the basal cell layer of the normal and hyperplastic human prostate , 2005, Virchows Archiv A.
[185] A. Wells,et al. In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals , 1995, Clinical & Experimental Metastasis.
[186] A. Levine. The tumor suppressor genes. , 1993, Annual review of biochemistry.
[187] C. Wilson,et al. Androgen Receptor Gene Expression in Human Prostate Carcinoma Cell Lines1 , 1990 .
[188] N. Block,et al. Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in explant cultures: reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. , 1993, Cancer research.
[189] J. Minna,et al. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. , 1988, Science.
[190] P. Boyle,et al. Incidence of prostate cancer will double by the year 2030: the argument for. , 1996, European urology.
[191] B. Groner,et al. Overexpression of the c‐erbB‐2 protein in human breast tumor cell lines , 1989, Journal of cellular biochemistry.
[192] J. Herman,et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. , 1995, Cancer research.
[193] J. Dodd,et al. Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines. , 1990, The Journal of urology.
[194] J. Isaacs,et al. Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide. , 1995, Cancer research.
[195] S. Dedhar,et al. The receptor for the basement membrane glycoprotein entactin is the integrin alpha 3/beta 1. , 1992, The Journal of biological chemistry.
[196] N. Block,et al. Association of elevated levels of hyaluronidase, a matrix-degrading enzyme, with prostate cancer progression. , 1996, Cancer research.
[197] F. S. French,et al. Expression of ras proto‐oncogenes in the dunning R3327 rat prostatic adenocarcinoma system , 1988, The Prostate.
[198] R. deVere White,et al. Flow cytometry as a predictive modality in prostate cancer. , 1992, Human pathology.
[199] L. Jin,et al. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. , 1992, Genomics.
[200] O. Chinot,et al. Divergent effect of TGFβ1 on growth and proteolytic modulation of human prostatic‐cancer cell lines , 1996 .
[201] W. J. Brammar,et al. The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours. , 1989, Oncogene.
[202] J. Schalken,et al. Decreased expression of the intercellular adhesion molecule E-cadherin in prostate cancer: Biological significance and clinical implications , 1993, Cancer and Metastasis Reviews.
[203] Y. Furuya,et al. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. , 1994, Cancer research.
[204] D. Yin,et al. Combination therapy with cisplatin and nifedipine induces apoptosis in cisplatin-sensitive and cisplatin-resistant human glioblastoma cells. , 1995, British Journal of Cancer.
[205] L. Chung,et al. Stromal-epithelial interactions--I. Induction of prostatic phenotype in urothelium of testicular feminized (Tfm/y) mice. , 1981, Journal of steroid biochemistry.
[206] G. Collina,et al. Sclerosing adenosis of the prostate. Report of three cases with electronmicroscopy and immunohistochemical study , 1992, Histopathology.
[207] W. Birchmeier,et al. E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton , 1994, The Journal of cell biology.
[208] P. Troncoso,et al. Trisomy 7: A potential cytogenetic marker of human prostate cancer progression , 1994, Genes, chromosomes & cancer.
[209] H. Wiley,et al. Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-alpha (TGF-alpha) and epidermal growth factor (EGF)/TGF-alpha receptor. , 1993, The Journal of clinical endocrinology and metabolism.
[210] N. Sato,et al. Androgen receptor gene mutations in human prostate cancer , 1993, The Journal of Steroid Biochemistry and Molecular Biology.
[211] K. Pienta,et al. A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell lines. , 1993, Cancer letters.
[212] E. Bergstralh,et al. Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer. , 1994, Cancer research.
[213] M. Stearns,et al. IL-10 blocks collagen IV invasion by "invasion stimulating factor" activated PC-3 ML cells: upregulation of TIMP-1 expression. , 1995, Oncology research.
[214] R. Nagle,et al. The α6β1 and α6β4 integrins in human prostate cancer progression , 1995, Cancer and Metastasis Reviews.
[215] W. Sakr,et al. DNA quantitation of intraepithelial neoplasia and invasive carcinoma of the prostate , 1993, The Prostate.
[216] H. Adami,et al. Perinatal characteristics in relation to incidence of and mortality from prostate cancer , 1996, BMJ.
[217] D. Pa,et al. Human prostatic endocrine-paracrine (APUD) cells. Distributional analysis with a comparison of serotonin and neuron-specific enolase immunoreactivity and silver stains. , 1985 .
[218] M. Brawer,et al. Expression of metalloproteinase genes in human prostate cancer , 2005, Journal of Cancer Research and Clinical Oncology.
[219] L. Eliasson,et al. Co‐localization of L‐type Ca2+ channels and insulin‐containing secretory granules and its significance for the initiation of exocytosis in mouse pancreatic B‐cells. , 1995, The EMBO journal.
[220] J. McNeal,et al. Differential cytokeratin expression in normal, hyperplastic and malignant epithelial cells from human prostate. , 1990, The Journal of urology.
[221] R. Weinberg,et al. Tumor suppressor genes. , 1991, Science.
[222] S. Friend,et al. Cancer risks from germline p53 mutations. , 1992, The Journal of clinical investigation.
[223] M. Watsky. Loss of keratocyte ion channels during wound healing in the rabbit cornea. , 1995, Investigative ophthalmology & visual science.
[224] B. Hille. Ionic channels of excitable membranes , 2001 .
[225] W. Catterall,et al. Calcium-dependent interaction of N-type calcium channels with the synaptic core complex , 1996, Nature.
[226] B. Oostra,et al. Trinucleotide (GGN) repeat polymorphism in the human androgen receptor (AR) gene. , 1993, Human molecular genetics.
[227] G. Folprecht,et al. Polarized ion transport during migration of transformed Madin-Darby canine kidney cells , 1995, Pflügers Archiv.
[228] J. Ross,et al. E-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage, and clinical outcome. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[229] O. Rokhlin,et al. Expression of cellular adhesion molecules on human prostate tumor cell lines , 1995, The Prostate.
[230] U. Stein,et al. Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate , 2005, Virchows Archiv A.
[231] K. Fischbeck,et al. Microsatellite mutation (CAG24-->18) in the androgen receptor gene in human prostate cancer. , 1994, Biochemical and biophysical research communications.
[232] T. Tsuruo,et al. Enhancement of voltage-gated Na+ channel current associated with multidrug resistance in human leukemia cells. , 1987, Cancer research.
[233] J. Mohler. Cellular motility and prostatic carcinoma metastases , 1993, Cancer and Metastasis Reviews.
[234] F. Schröder,et al. Detection of prostate cancer. , 1995, BMJ.
[235] J. Varley,et al. Structural rearrangement of the retinoblastoma gene in human breast carcinoma. , 1988, Science.
[236] E. Gelmann,et al. v-rasH expression confers hormone-independent in vitro growth to LNCaP prostate carcinoma cells. , 1991, Molecular endocrinology.
[237] V. P. Collins,et al. Allelotyping of human prostatic adenocarcinoma. , 1991, Genomics.
[238] J. Brooks,et al. Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas , 1995, The Prostate.
[239] R. Ueda,et al. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. , 1991, Oncogene.
[240] C R King,et al. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. , 1985, Science.
[241] A. Zlotta,et al. Prostatic intraepithelial neoplasia: influence of clinical and pathological data on the detection of prostate cancer. , 1996, The Journal of urology.
[242] J. Underwood. Diagnostic Molecular Pathology. A Practical Approach , 1993 .
[243] G. Haas,et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. , 1993, The Journal of urology.
[244] F. Schröder,et al. Neuroendocrine cells in the normal, hyperplastic and neoplastic prostate , 2004, Urological Research.
[245] S. H. Lin,et al. Tumor suppressive role of an androgen-regulated epithelial cell adhesion molecule (C-CAM) in prostate carcinoma cell revealed by sense and antisense approaches. , 1995, Cancer research.
[246] M. Hollstein,et al. Clinical implications of the p53 tumor-suppressor gene. , 1993, The New England journal of medicine.
[247] F. Habib,et al. Levels of circulating intercellular adhesion molecule-1 in patients with metastatic cancer of the prostate and benign prostatic hyperplasia. , 1995, European journal of cancer.
[248] M. Stearns,et al. Immunoassays of the metalloproteinase (MMP-2) and tissue inhibitor of metalloproteinase (TIMP 1 and 2) levels in noninvasive and metastatic PC-3 clones: effects of taxol. , 1994, Oncology research.
[249] W. Allsbrook,et al. Histochemistry of the prostate. , 1992, Human pathology.
[250] B A Miller,et al. The role of increasing detection in the rising incidence of prostate cancer. , 1995, JAMA.
[251] R. Hall. Screening and early detection of prostate cancer will decrease morbidity and mortality from prostate cancer: the argument against. , 1996, European urology.
[252] J. Isaacs,et al. Expression of a transfected v-Harvey-ras oncogene in a Dunning rat prostate adenocarcinoma and the development of high metastatic ability. , 1988, The Journal of urology.
[253] M. Litwin,et al. Identification of an endogenous inhibitor of prostatic carcinoma cell growth , 1995, Nature Medicine.
[254] C. Cordon-Cardo,et al. Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. , 1994, The Journal of urology.
[255] W. Isaacs,et al. Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: correlation with re-expression of alpha-catenin and restoration of E-cadherin function. , 1995, Cancer research.
[256] J. Isaacs,et al. Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. , 1995, Cancer research.
[257] T. Visakorpi,et al. Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas. , 1992, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[258] R. Matusik,et al. Expression of the c-myc proto-oncogene in prostatic tissue. , 1987, Progress in clinical and biological research.
[259] P C Prorok,et al. Prostate Cancer Screening: What We Know and What We Need To Know , 1993, Annals of Internal Medicine.
[260] A. Jenei,et al. Ion-channel activities regulate transmembrane signaling in thymocyte apoptosis and T-cell activation. , 1995, Immunology letters.
[261] I. Fidler,et al. Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells , 1995, The Journal of experimental medicine.
[262] A. Gown,et al. Monoclonal antibodies to human intermediate filament proteins. II. Distribution of filament proteins in normal human tissues. , 1984, The American journal of pathology.
[263] J. Crocker. Molecular biology in histopathology , 1994 .
[264] R. Nagle,et al. Differential expression of extracellular matrix molecules and the alpha 6-integrins in the normal and neoplastic prostate. , 1994, The American journal of pathology.
[265] T. Sekiya,et al. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. , 1989, Genomics.
[266] E. Corder,et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. , 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[267] K. Mullis,et al. Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. , 1987, Methods in enzymology.
[268] C. Foster,et al. Differential expression of voltage‐activated Na+ currents in two prostatic tumour cell lines: contribution to invasiveness in vitro , 1995, FEBS letters.
[269] K. Fan,et al. Heterogeneous subpopulations of human prostatic adenocarcinoma cells: potential usefulness of P21 protein as a predictor for bone metastasis. , 1988, The Journal of urology.
[270] R. Nagle,et al. Matrilysin expression in human prostate carcinoma , 1996, Molecular carcinogenesis.
[271] C. Bird,et al. Recombinant DNA technology and its diagnostic applications , 1992, Histopathology.
[272] J. Schalken,et al. Oncogene expression in prostate cancer , 1991, World Journal of Urology.
[273] Y. Hirata,et al. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. , 1993, The Journal of clinical investigation.
[274] N. Chamberlain,et al. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. , 1994, Nucleic acids research.
[275] Thomas,et al. Consistent expression of an epithelial cell adhesion molecule (C-CAM) during human prostate development and loss of expression in prostate cancer: implication as a tumor suppressor. , 1995, Cancer research.
[276] J. Mohler,et al. Prediction of metastatic potential by cancer cell motility in the Dunning R-3327 prostatic adenocarcinoma in vivo model. , 1992, The Journal of urology.
[277] G. Coetzee,et al. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. , 1995, Cancer research.
[278] E. Gelmann,et al. Differential effects of transforming growth factor β on human prostate cancer cells in vitro , 1989, Molecular and Cellular Endocrinology.
[279] R. Kiss,et al. In vitro characterization of prolactin‐induced effects on proliferation in the neoplastic LNCaP, DU145, and PC3 models of the human prostate , 1996, Cancer.
[280] A. Passaniti,et al. Immortalization of human adult prostatic adenocarcinoma cells by human papilloma virus HPV16 and -18 DNA. , 1996, Cancer letters.
[281] J. Epstein,et al. Use of Keratin 903 as an Adjunct in the Diagnosis of Prostate Carcinoma , 1989, The American journal of surgical pathology.
[282] F. Guillé,et al. Pretherapeutic erythrocyte polyamine spermine levels discriminate high risk relapsing patients with M1 prostate carcinoma , 1996, Cancer.
[283] J. Isaacs,et al. Role of calcium in the programmed death of rat prostatic glandular cells , 1990, The Prostate.
[284] G. Wilding,et al. Effects of Interferon βser and Transforming Growth Factor β on Prostatic Cell Lines , 1991 .
[285] T. Visakorpi,et al. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. , 1992, Journal of the National Cancer Institute.
[286] B. Vogelstein,et al. p53 mutations in human cancers. , 1991, Science.
[287] J. Epstein,et al. Utilization of high molecular weight cytokeratin on prostate needle biopsies in an independent laboratory. , 1995, Urology.
[288] W. Isaacs,et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. , 1994, Cancer research.
[289] N. Breslow,et al. Latent carcinoma of prostate at autopsy in seven areas. Collaborative study organized by the International Agency for Research on Cancer, Lyons, France , 1977, International journal of cancer.
[290] G. Miller,et al. Expression of c‐erb B‐2/neu proto‐oncogene in human prostatic cancer tissues and cell lines , 1992, Molecular carcinogenesis.
[291] A. Schally,et al. Inhibitory effects of analogs of luteinizing hormone‐releasing hormone on the growth of the androgen‐independent dunning R‐3327‐AT‐1 rat prostate cancer , 1994, International journal of cancer.
[292] S. Soker,et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. , 1995, Cancer research.
[293] S. Rabbani,et al. Induction of urinary plasminogen activator by retinoic acid results in increased invasiveness of human prostate cancer cells PC‐3 , 1995, The Prostate.
[294] G. Cunha. Epithelial-stromal interactions in development of the urogenital tract. , 1976, International review of cytology.
[295] H. Nordgren,et al. In situ expression of mRNA for proto-oncogenes in benign prostatic hyperplasia and in prostatic carcinoma. , 1991, Scandinavian journal of urology and nephrology.
[296] F. Bosman,et al. Loss of heterozygosity of chromosome 8 microsatellite loci implicates a candidate tumor suppressor gene between the loci D8S87 and D8S133 in human prostate cancer. , 1994, Cancer research.
[297] J. Folkman,et al. A strategy to discover circulating angiogenesis inhibitors generated by human tumors. , 1995, Cancer research.
[298] W. Isaacs,et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. , 1992, Cancer research.
[299] A. Passaniti,et al. Antiangiogenic effects of the quinoline-3-carboxamide linomide. , 1993, Cancer research.
[300] F. Bosman,et al. Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer , 1994, International journal of cancer.
[301] H. Naiki,et al. Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. , 1992, Cancer research.
[302] T. Stamey,et al. Clonal growth of human prostatic epithelial cells is stimulated by fibroblasts , 1989, The Prostate.
[303] C. Blat,et al. IGF-I and IGF-binding proteins: stimulatory and inhibitory factors secreted by human prostatic adenocarcinoma cells. , 1991, Growth factors.
[304] D. Djakiew,et al. Chemotaxis and chemokinesis of human prostate tumor cell lines in response to human prostate stromal cell secretory proteins containing a nerve growth factor-like protein. , 1993, Cancer research.
[305] J. McNeal,et al. Normal histology of the prostate. , 1988, The American journal of surgical pathology.
[306] W. Catterall,et al. Structure and function of the β2 subunit of brain sodium channels, a transmembrane glycoprotein with a CAM motif , 1995, Cell.
[307] C. Eaton,et al. Growth Factor Receptors and Oncogene Expression in Prostate Cells , 1988, American journal of clinical oncology.
[308] L. Donehower,et al. The tumore suppressor p53 , 1993 .
[309] M. Brawer,et al. Serum basic fibroblast growth factor in men with and without prostate carcinoma , 1995, Cancer.
[310] M. Gleave,et al. Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis. , 1992, The Journal of urology.
[311] C. Polychronakos,et al. Mitogenic effects of insulin and insulin‐like growth factors on PA‐III rat prostate adenocarcinoma cells: Characterization of the receptors involved , 1991, The Prostate.
[312] L. Strong,et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.
[313] J. Bishop. Molecular themes in oncogenesis , 1991, Cell.
[314] G. Bubley,et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.
[315] David J. Grignon,et al. The Prostatic Capsule: Does It Exist? Its Importance in the Staging and Treatment of Prostatic Carcinoma , 1989, The American journal of surgical pathology.
[316] T M Grogan,et al. Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. , 1993, Cancer research.
[317] J. Ward,et al. K‐ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men , 1992, Cancer.
[318] P. Troncoso,et al. Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy. , 1994, Urology.
[319] J. Yokota,et al. Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung. , 1988, Oncogene.
[320] J. Estève,et al. Cancer in the European Community and its member states. , 1990, European journal of cancer.
[321] R. Nagle,et al. Characterization of integrin subunits, cellular adhesion and tumorgenicity of four human prostate cell lines , 1993, Journal of Cancer Research and Clinical Oncology.
[322] Michael J. Wilson,et al. Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: Increased PA activity correlates with biologically aggressive behavior , 1991, The Prostate.
[323] H. Dvorak,et al. Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen. , 1995, The Journal of urology.
[324] P. Sluss,et al. Insulin‐like growth factor I: Action and receptor characterization in human prostate cancer cell lines , 1993, The Prostate.
[325] M. Gleave,et al. Reciprocal mesenchymal-epithelial interaction affecting prostate tumour growth and hormonal responsiveness. , 1991, Cancer surveys.
[326] D. Neal,et al. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. , 1992, The Journal of urology.
[327] P. Boyle,et al. Screening for prostate cancer--necessity or nonsense? , 1993, European journal of cancer.
[328] P. di Sant'Agnese,et al. Neuroendocrine cells in the human prostate gland. , 1993, Journal of andrology.
[329] W. Fair,et al. Expression of the prostate-specific membrane antigen. , 1994, Cancer research.
[330] N. Block,et al. Detection of prostatic‐inhibin‐like peptide in the cytoplasm of LNCaP cells, a human prostatic adenocarcinoma cell line , 1994, The Prostate.
[331] J. Brooks,et al. Genetic alterations in prostate cancer. , 1994, Cold Spring Harbor symposia on quantitative biology.
[332] J. L. Bos,et al. ras oncogenes in human cancer: a review. , 1989, Cancer research.
[333] T. Lüscher,et al. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. , 1990, The Journal of clinical investigation.
[334] M. Masai,et al. Histochemical examination of expression of ras p21 protein and R 1881-binding protein in human prostatic cancers. , 1990, European journal of cancer.
[335] M. Viola,et al. Expression of ras oncogene p21 in prostate cancer. , 1986, The New England journal of medicine.
[336] Schr,et al. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. , 1994, The American journal of pathology.
[337] A. Partin,et al. Prediction of metastatic potential in an animal model of prostate cancer: flow cytometric quantification of cell surface charge. , 1989, The Journal of urology.
[338] H. Lepor,et al. Localization of endothelin receptors in the human prostate. , 1994, The Journal of urology.
[339] S. Hilsenbeck,et al. p53 is mutated in a subset of advanced-stage prostate cancers. , 1993, Cancer research.
[340] I. Nishimoto,et al. Activation of a calcium-permeable cation channel by insulin-like growth factor II in BALB/c 3T3 cells. , 1988, The American journal of physiology.
[341] M. Benson,et al. Calcium channel antagonists delay regression of androgen‐dependent tissues and suppress gene activity associated with cell death , 1988, The Prostate.
[342] D. Djakiew,et al. Distribution of nerve growth factor-like protein and nerve growth factor receptor in human benign prostatic hyperplasia and prostatic adenocarcinoma. , 1992, The Journal of urology.
[343] T. H. van der Kwast,et al. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. , 1991, Molecular endocrinology.
[344] B. Zetter,et al. Selective stimulation of prostatic carcinoma cell proliferation by transferrin. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[345] T. Tsujii,et al. [The clinical usefulness of urinary basic fetoprotein (BFP) in patients with urological malignancies]. , 1990, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.
[346] C. Tso,et al. Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. , 1995, Human gene therapy.
[347] K. Yamamoto,et al. Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA , 2003, Nature.
[348] N. Bruchovsky,et al. DNA content in prostatic adenocarcinoma. A flow cytometry study of the predictive value of aneuploidy for tumor volume, percentage gleason grade 4 and 5, and lymph node metastases , 1990, Cancer.
[349] M. Goligorsky,et al. Termination of endothelin signaling: Role of nitric oxide , 1994, Journal of cellular physiology.
[350] M. Wigler,et al. Cloning the differences between two complex genomes , 1993, Science.
[351] D. Rose,et al. Secretion of epidermal growth factor and related polypeptides by the DU 145 human prostate cancer cell line , 1989, The Prostate.
[352] D. Bostwick,et al. The association of benign prostatic hyperplasia and cancer of the prostate , 1992, Cancer.
[353] R. deVere White,et al. Activated ras alleles in human carcinoma of the prostate are rare. , 1991, Cancer research.
[354] R. Hoover,et al. Farming and prostate cancer among African-Americans in the southeastern United States. , 1994, Journal of the National Cancer Institute.
[355] R. Leake,et al. Transforming growth factor-α expression in benign and malignant human prostatic disease , 1992 .
[356] K. Ching,et al. Expression of mRNA for epidermal growth factor, transforming growth factor-alpha and their receptor in human prostate tissue and cell lines , 1993, Molecular and Cellular Biochemistry.
[357] Chung Lee,et al. Genetic change in transforming growth factor β (TGF-β) receptor type I gene correlates with insensitivity to TGF-β1 in human prostate cancer cells , 1996 .
[358] E. Dmitrovsky,et al. Isochromosome of Chromosome 12: Clinically Useful Marker for Male Germ Cell Tumors , 1989 .
[359] P. Smith,et al. Intranuclear androgen receptor deployment and protooncogene expression in human diseased prostate. , 1987, Urologia internationalis.
[360] N. Weidner,et al. Concordance of DNA content between prostatic intraepithelial neoplasia and concomitant invasive carcinoma. Evidence that prostatic intraepithelial neoplasia is a precursor of invasive prostatic carcinoma. , 1993, Archives of pathology & laboratory medicine.
[361] D. S. Coffey,et al. Cell surface charge in predicting metastatic potential of aspirated cells from the Dunning rat prostatic adenocarcinoma model. , 1988, The Journal of urology.
[362] D. Grignon,et al. Usefulness of immunoperoxidase staining with high-molecular-weight cytokeratin in the differential diagnosis of small-acinar lesions of the prostate gland , 2005, Virchows Archiv A.
[363] D. Peehl,et al. The IGF axis in the prostate. , 1994, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[364] S. Maygarden,et al. Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate. , 1991, Human pathology.
[365] W. Whitmore. Natural history of low-stage prostatic cancer and the impact of early detection. , 1990, The Urologic clinics of North America.
[366] R. Nagle,et al. Cytokeratin characterization of human prostatic carcinoma and its derived cell lines. , 1987, Cancer research.